Deciphering the impact of aging and inflammation on neurocognitive impairments in people with Post-Acute Sequelae of COVID-19 (PASC)

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 202111WI3

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2023
  • Known Financial Commitments (USD)

    $393,435.8
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    N/A

  • Research Location

    Canada
  • Lead Research Institution

    University of Alberta
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

www.cbc.ca/player/play/1970781763780](http://www.cbc.ca/player/play/1970781763780)). It is also unclear to what extent brain damage occurs during acute COVID-19 and its contribution to long term consequences of COVID-19, termed 'long covid' or post-acute sequelae of COVID-19 (PASC). Nonetheless, these brain disabilities can prevent people with PASC from returning to work and regular day-to-day activities together with causing depressed mood, social isolation and increased use of the healthcare system. Our proposed research will examine the fundamental disease mechanisms in the brain during COVID-19 using autopsied brain tissues and a mouse model of COVID-19. In people with PASC, we will study the frequency, severity, types of brain function abnormalities using psychological testing. In addition, we will discover risk factors and signs of brain abnormalities measured in the blood in relation to aging and brain resilience or adaptability that can guide diagnosis and treatments. We are a multidisciplinary team and are comprised of early, mid, and senior clinical and experimental researchers with unique expertise in Canada. In fact, our preliminary data show marked inflammation in the brains of humans dying with COVID-19. These proposed studies will discover the disease pathways that cause the brain function abnormalities in people with PASC and will lead to a better understanding of PASC-associated brain problems and new treatment approaches.